PDF(1117 KB)
PDF(1117 KB)
PDF(1117 KB)
羟乙基淀粉质量研究进展
Overview of the Quality Study on Hydroxyethyl Starches
羟乙基淀粉(hydroxyethyl starches,HES)是支链淀粉经改性而得的一种高分子聚合物,具有强效快速的持续扩容效果,现被广泛应用于治疗和预防血容量不足,急性等容血液稀释(ANH)等。但由于存在肾脏及凝血功能等方面的潜在威胁,近年来一直备受关注与争议。笔者将对国内外HES产品的发展及质量研究概况进行阐述,以现行的国内各企业标准及《欧洲药典》(EP)标准为基础,着重介绍重均相对分子质量(Mw)与相对分子质量分布、羟乙基化程度(摩尔取代度MS)、羟乙基化具体位点(C2/C6)和含量测定的质控现状,并结合本课题组的探索性研究工作,给出各项目的质控方法建议,为该产品的质量标准提高及研究提供一定的思路,以保证其安全有效。
Hydroxyethyl starches(HES) are modified natural polymer of amylopectin with volume expansion properties. It has been widely used in the treatment for prevention of hypovolemia and acute normovolemic hemodilution(ANH). However, the potential threats to kidney and coagulation have attracted much attention and controversy in recent years. This review will focus on the specification development and quality study of HES. The article will mainly talk about some quality control items: molecular weight (Mw) and molecular weight distribution, degree of hydroxyethyl (molar substitution, MS), the specific sites of hydroxyethylation (C2/C6 ratio) and assay, all of those are based on the domestic enterprise standards and Europe Pharmacopoeia(EP), and we will combine with the experimental data to give some suggestions on these items quality control. Hopefully to provide some ideas for improving and unifying the quality standard of hydroxyethyl starches.
羟乙基淀粉 / 摩尔取代度 / 羟乙基化位点C2/C6 / 含量测定 / 质量控制 {{custom_keyword}} /
hydroxyethyl starch / molar substitution / C2/C6 / assay / quality control {{custom_keyword}} /
[1] JOACHIM B, ANDREAS L, FRANK L, et al. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass[J]. J Cardioth Vascul Anesth, 2000, 14(3):264-268.
[2] JOACHIM B. PRO:hydroxyethyl starch can be safely used in the intensive care patient-the renal debate[J].Intensive Care Med, 2009, 35(8):1331-1336.
[3] MCLLROY D, KHARASCH E. Acute intravascular volume expansion with rapidly administered crystalloid and colloid in the setting of moderate hypovolemia[J]. Anesth Analg, 2003, 96(6):1572-1577.
[4] WU Z H. Modern concept of fluid replacement in the surgical patients[J]. J Surg Concept Pract(外科理论与实践), 2004, 9(4):343-344.
[5] SCHORTGEN F, DEYE N, BROCHARD L. Prefered plasma volume expanders for critically ill payients:results of an international survey[J]. Intensive Care Med, 2004, 30(12):2222-2229.
[6] WU C S, WU T. The research progress of HES130/0.4[J]. Chin J New Drugs(中国新药杂志), 2005, 14(8):981-984.
[7] ZHANG L. Analysis of the production and marketing of hydroxyethyl starch[J]. Chin Pharm Inf(中国制药信息), 2015, 35(1):24-29.
[8] CORNELIUS J, THOMAS A N. Pharmacokinetics of hydroxyethyl starch[J]. Clin Pharmacokinet, 2005, 44(7):681-699.
[9] KUZMINA N E, MOISEEV S V, KRYLOV V I, et al. Validation of a method for measuring the molar substitution of hydroxythyl starch by 1H-NMR spectroscopy[J].Pharm Chem J, 2016, 50(4):265-269.
[10] MARTIN W, MICHAEL F M J, SIBYLLE K L, et al. Hydroxyethyl starches:different products-different effects[J]. Anesthesiol, 2009, 111(1):187-202.
[11] ZHOU X, ZHANG X L. The clinical studies of hydroxyethyl starchesa plasma volume expander [J].Chin Pharm J(中国药学杂志), 2007, 42(9):646-649.
[12] JOACHIM B, HAISCH G, SUTTNER S, et al. Effects of a new modified, balanced hydroxyethyl starch preparation(Hextend) on measures of coagulation[J].Br J Anaesth, 2002, 89(5):722-728.
[13] MAHLON M W, ROBERTA J N, WILLIAM J S. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a Meta-analysis of postoperative bleeding[J].Ann Thorac Surg, 2001, 72(2):527-534.
[14] TREIB J, BARON J F, GRAUER M T, et al. An international view of hydroxyethyl starches[J].Intensive Care Med, 1999, 25(3):258-268.
[15] SIBYLLE A K L, CORNELIUS J, WILHELM S, et al. The effects of hydroxyethyl starch 130/0.4(6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials[J].Anesth Analg, 2008, 107(2):382-390.
[16] LEHMANN G, MARX G, FORSTER H. Bioequivalence comparison between hydroxyethyl starch 130/0.42/6:1 and hydroxyethyl starch 130/0.4/9:1[J].Drugs Res Develop, 2007, 8(4):229-240.
[17] CFDA. Hydroxyethyl starch 40/20 sodium chloride injection and renal function damage(羟乙基淀粉40、20氯化钠注射液与肾功能损害)[ES/OL].(2005-04-12). http://www.sda.gov.cn/WS01/CL0078/11280.html.
[18] FRANZISKA S, JANAINA O, FABIO T, et al. Effects of a predominantly hydroxyethyl starch(HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients[J].Intensive Care Med, 2009, 35(9):1539-1547.
[19] ROTEN I, MADJBPOUR C, FRASCAROLO P, et al. Molar substitution and C2/C6 ratio of hydroxyethyl starch:influence on blood coagulation[J].Br J Anaesth, 2006, 96(4):455-463.
[20] EMA. Hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients[ES/OL].(2013.10.23) http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Hydroxyethyl_starch-containing_solutions/human_referral_prac_000012.jsp&mid=WC0b01ac05805c516f.
[21] CFDA. The state administration of food and drug administration has warned about the safety risks of hydroxyethyl starch(国家食品药品监督管理总局提醒关注含羟乙基淀粉类药品安全风险)[ES/OL].(2014-02-26). http://www.sfda.gov.cn/WS01/CL0051/97074.html
[22] EMA. PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market[ES/OL].(2018-01-12). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/01/news_detail_002882.jsp&mid=WC0b01ac058004d5c1
[23] EMA. Hydroxyethyl-starch solutions for infusion to be suspended-CMDh endorses PRAC recommendation[ES/OL].(2018-01-26). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/01/news_detail_002892.jsp&mid=WC0b01ac058004d5c1
[24] EMA. PRAC to further consider unmet medical needs for hydroxyethyl-starch (HES) solutions for infusion[ES/OL].(2018-04-13). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/04/news_detail_002938.jsp&mid=WC0b01ac058004d5c1.
[25] ROMUALD B, CLEMENS F, CHRISTIAN J W. Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch[J].Clin Pharm, 2012, 51(4):225-236.
[26] FAN H H, LI J. Determination of molecular weight and molecular weight distribution of polysaccharides[Z].National Institutes for Food and Drug Control(中国食品药品检定研究院), 2000.
[27] SHI L H. Gel Chromatography(凝胶色谱)[M]. Beijing:Science Press, 1980.
[28] STEPHEN E H, GARY G A, RICHARD B G. Molecular weight analysis of starches: which technique?[J]. Starch/St rke, 2016, 68(9-10):846-853.
[29] EP7.0 Vol Ⅱ(2010)[S].2010:2984-2988.
[30] YING C L, DAVID M B, JAMES E C. Determination of the molar substitution of hydroxyethyl starches by gas chromatography[J]. Anal Chem, 1983, 55(2):334-338.
[31] The People′s Republic of China Ministry of Health Pharmaceutical Standards Volume Ⅱ sixth (1998)(1988年中华人民共和国药品标准二部第六册生化药品第一分册)[S].1998:125.
[32] YOSHIDA M, YAMASHITA T, MATSUO J, et al.Enzymic degradation of hydroxuethyl starch:Part Ⅰ.Influence of the distribution of hydroxyethyl groups on the enzymic degradation of hydroxyethyl starch[J].St rke, 1973, 25(11):373-376.
[33] DU L W, HUANG Z P, YANG H Y, et al. The assaying of hydroxyethyl starch 200/0.5 using polarimetry[J].Pract Pharm Clin Rem(实用药物与临床), 2009, 12(1):35.
[34] XV D Q, BO Y M, ZHANG Z C. Study on the method of measuring the content of hydroxyethyl starch[J]. J Mudanjiang Med Coll(牡丹江医学院学报), 1994, 15(3):8-9.
国家重大新药创制项目资助(2015ZX09030001)
/
| 〈 |
|
〉 |
